
Opinion|Videos|January 24, 2025
Impact of Safety Profiles on BTK Inhibitor Selection in R/R CLL
Panelists discuss how distinct safety profiles among Bruton tyrosine kinase (BTK) inhibitors—including variations in cardiovascular effects, bleeding risk, infection susceptibility, and other adverse events—guide personalized treatment decisions in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) based on individual comorbidities and risk factors.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How do differences in safety profiles between BTK inhibitors influence treatment selection in R/R CLL?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Misinformation and Knowledge Gaps Undermine Vaccine Protection: Kristina Crothers, MD
2
Proactive MG Management Hinges on Better Coverage and Guidelines
3
Patients, Providers Strongly Favor Oral Therapies in Psoriasis
4
Energy Insecurity Linked to Higher Depression, Anxiety in US Adults
5















































